|
# # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during November 2022. The post is divided into 10 parts based on the type of research:
# # # # |
So, what happened during November 2022?
In world news:
November 11th – The cryptocurrency exchange FTX (once valued at $18 billion) filed for Chapter 11 bankruptcy, in a collapse that affected the entire cryptocurrency environment.
November 15th – the world’s population of humans reached 8 billion.
November 16th – NASA launches Artemis 1, the first uncrewed mission of its Space Launch System, the most powerful rocket ever to reach orbit. The onboard Orion capsule orbits the Moon before returning to Earth, as a demonstration of planned human missions. The image below is of the far side of the moon visible beyond the Orion spacecraft on the 21st November:
November 29th – Biotech companies Eisai and Biogen published the results of their Phase 3 study of Lecanemab. They reported that it “reduced markers of amyloid in early Alzheimer’s disease and resulted in moderately less decline on measures of cognition and function than placebo at 18 months but was associated with adverse events” (Click here to read more about this).
November 30th – OpenAI released a prototype of an artificial intelligence chatbot called ChatGPT, capable of answering questions and write essays in real time…. is this the end of the Science of PD?
In the world of Parkinson’s research, a great deal of new research and news was reported:
In November 2022, there were 901 research articles added to the Pubmed website with the tag word “Parkinson’s” attached (9785 for all of 2022 so far). In addition, there was a wave to news reports regarding various other bits of Parkinson’s research activity (clinical trials, etc).




































